TextSearch

Gilead Sciences Stock exchange: NASDAQ ・ Ticker: GILD ・ HQ: Foster City, California, United States ・ Access to Medicine Index 16 Rank 2.21 Score The full report card of Gilead Sciences in PDF format. Download the report card Performance in the 2024 Index16th place. Gilead performs below average. It engages widely in voluntary licensing to enable generic supply. However, it has a comparatively poor performance in Governance of Access, and many of its late-stage pipeline projects do not have an access plan. Opportunities for GileadEnsure all late-stage R&D projects have comprehensive access plans. Gilead has a structured framework for access planning. However, it only has access plans in place for 10% of its late-stage R&D projects. By implementing its systematic framework for access planning, the company can ensure the coverage of all pipeline projects from Phase II onwards. For example, Gilead can disclose access plans to its innovative drug domvanalimab, currently undergoing clinical trials for multiple cancer indications. Ensure access-to-medicine strategy is integrated within its corporate strategy. Gilead's access strategy has a business rationale, which covers some therapeutic areas that the company is involved in. The company can ensure the strategy is integrated into its corporate strategy and expand it to all therapeutic areas. Ensure equitable access to lenacapavir in low- and middle-income countries (LMICs). Gilead’s blockbuster long-acting injectable, lenacapavir, is currently approved for HIV treatment and has demonstrated promising results in clinical trials for HIV prevention. The company has publicly announced a non-exclusive voluntary licensing agreement with six generic manufacturers to make and sell generic lenacapavir in 120 LMICs (subject to regulatory approvals). It can now work (alongside the generic sublicensees) to ensure fast and equitable access to generic lenacapavir. Furthermore, it must ensure access to affordable lenacapavir, particularly for vulnerable populations living in countries outside of the licensing agreement. Changes since the 2022 IndexEndorsed the Kigali Declaration on Preventing, Controlling, and Eliminating Neglected Tropical Diseases in June 2022.Contributed USD 85mn to the Gilead Foundation to advance health equity. Announced a new public-private initiative with the Partnership for Health Advancement in Vietnam to help address barriers that limit viral hepatitis diagnosis and care at primary healthcare facilities in Vietnam and the Philippines. Expanded its ongoing long-term donation programme of amphotericin B liposome (AmBisome®) to two additional countries in scope (Eritrea and Yemen) in 2023 to support the elimination of visceral leishmaniasis. In June 2024, Gilead’s Phase III clinical trial PURPOSE 1, which evaluated the twice-yearly injection Lenacapavir, demonstrated 100% efficacy in preventing HIV infection in cisgender women (a group that shares a disproportionate number of new HIV infections). In October 2024, after the period of analysis,* announced it had signed non-exclusive voluntary licensing (NEVL) agreements with six generic manufacturers to make and sell generic lenacapavir. The licence covers lenacapavir for HIV prevention (subject to required regulatory approvals) and for HIV treatment in heavily treatment-experienced adults with multi-drug resistant HIV. The licence covers 120 countries, including 96 counties in scope of the Index.**In October 2024, Gilead announced an additional non-exclusive voluntary licensing agreement for lenacapavir. As the licence was announced after the period of analysis concluded, it was not assessed as part of the 2024 Access to Medicine Index. Sales and OperationsTherapeutic areas: Inflammatory diseases, oncology, viral diseases Product categories: Innovative medicines M&A news: Gilead acquired the remaining worldwide rights of Trodelvy® from Everest Medicines for USD 175mn and MiroBio for USD 405mn in 2022, respectively. In 2023, it acquired Tmunity Therapeutics and XinThera for undisclosed amounts. In 2024 Gilead acquired CymaBay Therapeutics Inc for USD 4.3bn. Revenue by segment (2023) – in USD Pharmaceutical 27.12 bn Total 27.12 bn Sample of pipeline and portfolio assessed by the IndexPIPELINE for diseases in scopeGilead has 44 R&D projects in scope, 20 of which target priority diseases, focusing on HIV/AIDS (15) and COVID-19 (4). The remaining 24 projects target other diseases in scope, including cancer (19), hepatitis B (4) and HIV/AIDS (1). Of the 44 R&D projects, 29 are in late-stage development, with evidence of access planning for 10% (3/29) of these. PORTFOLIO as selected for analysis by the IndexGilead has 20 medicines in scope, 7 of which are listed on the WHO EML. Most of the company’s medicines are on patent (17). Its medicines primarily treat communicable diseases, such as HIV (9), hepatitis B and C (5) and 1 medicine is indicated for both HIV and hepatitis B (1). Its medicines for non-communicab...